|
DE19624659A1
(de)
|
1996-06-20 |
1998-01-08 |
Klinge Co Chem Pharm Fab |
Neue Pyridylalken- und Pyridylalkinsäureamide
|
|
US6451816B1
(en)
|
1997-06-20 |
2002-09-17 |
Klinge Pharma Gmbh |
Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
|
|
JPH10338658A
(ja)
*
|
1997-04-08 |
1998-12-22 |
Hoechst Marion Roussel Kk |
レチノイド作用調節剤
|
|
DE19756235A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
|
|
DE19756261A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
|
|
US6903118B1
(en)
|
1997-12-17 |
2005-06-07 |
Klinge Pharma Gmbh |
Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
|
|
DE19756212A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19818044A1
(de)
*
|
1998-04-22 |
1999-10-28 |
Klinge Co Chem Pharm Fab |
Verwendung von Vitamin-PP-Verbindungen
|
|
JP2002522499A
(ja)
*
|
1998-08-12 |
2002-07-23 |
スミスクライン・ビーチャム・コーポレイション |
カルシウム分解化合物
|
|
DE19908483A1
(de)
*
|
1999-02-26 |
2000-10-05 |
Klinge Co Chem Pharm Fab |
Inhibitoren der zellulären Niacinamidmononucleotid-Bildung
|
|
EP1031564A1
(en)
*
|
1999-02-26 |
2000-08-30 |
Klinge Pharma GmbH |
Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
|
|
US6511986B2
(en)
|
2000-08-11 |
2003-01-28 |
Wyeth |
Method of treating estrogen receptor positive carcinoma
|
|
JP5089846B2
(ja)
|
2000-09-29 |
2012-12-05 |
グラクソ グループ リミテッド |
炎症性疾患を処置するためのモルホリン−アセトアミド誘導体
|
|
EP1348434A1
(en)
*
|
2002-03-27 |
2003-10-01 |
Fujisawa Deutschland GmbH |
Use of pyridyl amides as inhibitors of angiogenesis
|
|
GB0207445D0
(en)
*
|
2002-03-28 |
2002-05-08 |
Glaxo Group Ltd |
Novel compounds
|
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
|
EA200701745A1
(ru)
|
2005-03-17 |
2008-06-30 |
Пфайзер, Инк. |
Циклопропанкарбоксамидные производные
|
|
PE20071159A1
(es)
|
2005-10-31 |
2007-11-30 |
Schering Corp |
Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
|
|
WO2007053499A2
(en)
|
2005-11-01 |
2007-05-10 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of ccr2
|
|
WO2007053498A1
(en)
|
2005-11-01 |
2007-05-10 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of ccr2
|
|
HUP0600809A3
(en)
*
|
2006-10-27 |
2008-09-29 |
Richter Gedeon Nyrt |
New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
|
|
EP2098231A1
(en)
|
2008-03-05 |
2009-09-09 |
Topotarget Switzerland SA |
Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
|
|
EP2318369A1
(en)
|
2008-06-24 |
2011-05-11 |
TopoTarget A/S |
Squaric acid derivatives as inhibitors of the nicotinamide
|
|
US8871747B2
(en)
|
2008-08-29 |
2014-10-28 |
Topotarget A/S |
Urea and thiourea derivatives
|
|
WO2011006988A1
(en)
|
2009-07-17 |
2011-01-20 |
Topotarget A/S |
Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
|
|
WO2011121055A1
(en)
|
2010-03-31 |
2011-10-06 |
Topotarget A/S |
Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
|
|
TW201216963A
(en)
|
2010-09-03 |
2012-05-01 |
Forma Therapeutics Inc |
Novel compounds and compositions for the inhibition of NAMPT
|
|
RU2617424C2
(ru)
|
2010-09-03 |
2017-04-25 |
ФОРМА ТиЭм, ЭлЭлСИ |
Новые соединения и композиции для ингибирования nampt
|
|
WO2012031197A1
(en)
|
2010-09-03 |
2012-03-08 |
Forma Therapeutics, Inc. |
Novel compounds and compositions for the inhibition of nampt
|
|
CA2811369C
(en)
*
|
2010-09-29 |
2019-09-03 |
Intervet International B.V. |
N-heteroaryl compounds
|
|
CN103313968A
(zh)
|
2010-11-15 |
2013-09-18 |
Abbvie公司 |
Nampt和rock抑制剂
|
|
US20120122924A1
(en)
|
2010-11-15 |
2012-05-17 |
Abbott Laboratories |
Nampt inhibitors
|
|
MX2013012760A
(es)
|
2011-05-04 |
2014-03-12 |
Forma Tm Llc |
Nuevos compuestos y composiciones para la inhibicion de nampt.
|
|
US9555039B2
(en)
|
2011-05-09 |
2017-01-31 |
Forma Tm, Llc. |
Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
|
|
UY34804A
(es)
|
2012-05-11 |
2013-12-31 |
Abbvie Inc |
Inhibidores del nampt
|
|
MX2014013758A
(es)
|
2012-05-11 |
2015-02-05 |
Abbvie Inc |
Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
|
|
RU2014150049A
(ru)
|
2012-05-11 |
2016-07-10 |
Эббви Инк. |
Ингибиторы nampt
|
|
JP2015516436A
(ja)
|
2012-05-11 |
2015-06-11 |
アッヴィ・インコーポレイテッド |
Ｎａｍｐｔ阻害薬
|
|
WO2014085607A1
(en)
|
2012-11-29 |
2014-06-05 |
Karyopharm Therapeutics Inc. |
Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
|
|
KR102325247B1
(ko)
|
2013-07-03 |
2021-11-11 |
카리오팜 쎄라퓨틱스, 인코포레이티드 |
치환된 벤조퓨라닐 및 벤즈옥사졸릴 화합물 및 이의 용도
|
|
WO2015042414A1
(en)
|
2013-09-20 |
2015-03-26 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and methods of using same
|
|
WO2017031323A1
(en)
|
2015-08-18 |
2017-02-23 |
Karyopharm Therapeutics Inc. |
(s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
|
|
WO2017117447A1
(en)
|
2015-12-31 |
2017-07-06 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and uses thereof
|
|
SG11201903013SA
(en)
|
2016-10-18 |
2019-05-30 |
Seattle Genetics Inc |
Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
|
|
WO2018086703A1
(en)
|
2016-11-11 |
2018-05-17 |
Bayer Pharma Aktiengesellschaft |
Dihydropyridazinones substituted with phenylureas
|
|
BR112019022445A2
(pt)
|
2017-04-27 |
2020-05-12 |
Seattle Genetics, Inc. |
Composição de conjugado ligante-fármaco, formulação, método para inibir a multiplicação de uma célula tumoral ou célula cancerosa ou causar apoptose em uma célula tumoral ou cancerosa, e, composto de conector de fármaco
|
|
EP3746079A1
(en)
|
2018-01-31 |
2020-12-09 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
KR102831570B1
(ko)
|
2018-05-04 |
2025-07-10 |
레미디 플랜, 인크. |
암 줄기 세포를 표적화하는 암 치료
|
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
MX2022005445A
(es)
|
2019-11-06 |
2022-08-10 |
Remedy Plan Inc |
Tratamientos contra el cáncer dirigidos a las células madre cancerosas.
|
|
CA3217380A1
(en)
|
2021-05-13 |
2022-11-17 |
Yushma Bhurruth-Alcor |
Nampt inhibitors and uses thereof
|